Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gender as a disease modifier in neurofibromatosis type 1 optic pathway glioma.
Fisher MJ, Loguidice M, Gutmann DH, Listernick R, Ferner RE, Ullrich NJ, Packer RJ, Tabori U, Hoffman RO, Ardern-Holmes SL, Hummel TR, Hargrave DR, Bouffet E, Charrow J, Bilaniuk LT, Balcer LJ, D'Agostino McGowan L, Liu GT. Fisher MJ, et al. Among authors: ardern holmes sl. Ann Neurol. 2014 May;75(5):799-800. doi: 10.1002/ana.24157. Epub 2014 May 14. Ann Neurol. 2014. PMID: 24740685 No abstract available.
CSF neopterin, quinolinic acid and kynurenine/tryptophan ratio are biomarkers of active neuroinflammation.
Yan J, Kothur K, Mohammad S, Chung J, Patel S, Jones HF, Keating BA, Han VX, Webster R, Ardern-Holmes S, Antony J, Menezes MP, Tantsis E, Gill D, Gupta S, Kandula T, Sampaio H, Farrar MA, Troedson C, Andrews PI, Pillai SC, Heng B, Guillemin GJ, Guller A, Bandodkar S, Dale RC. Yan J, et al. EBioMedicine. 2023 May;91:104589. doi: 10.1016/j.ebiom.2023.104589. Epub 2023 Apr 27. EBioMedicine. 2023. PMID: 37119734 Free PMC article.
Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis.
Fisher MJ, Loguidice M, Gutmann DH, Listernick R, Ferner RE, Ullrich NJ, Packer RJ, Tabori U, Hoffman RO, Ardern-Holmes SL, Hummel TR, Hargrave DR, Bouffet E, Charrow J, Bilaniuk LT, Balcer LJ, Liu GT. Fisher MJ, et al. Among authors: ardern holmes sl. Neuro Oncol. 2012 Jun;14(6):790-7. doi: 10.1093/neuonc/nos076. Epub 2012 Apr 3. Neuro Oncol. 2012. PMID: 22474213 Free PMC article.
Functional outcome measures for NF1-associated optic pathway glioma clinical trials.
Fisher MJ, Avery RA, Allen JC, Ardern-Holmes SL, Bilaniuk LT, Ferner RE, Gutmann DH, Listernick R, Martin S, Ullrich NJ, Liu GT; REiNS International Collaboration. Fisher MJ, et al. Among authors: ardern holmes sl. Neurology. 2013 Nov 19;81(21 Suppl 1):S15-24. doi: 10.1212/01.wnl.0000435745.95155.b8. Neurology. 2013. PMID: 24249802 Free PMC article.
Hearing and facial function outcomes for neurofibromatosis 2 clinical trials.
Plotkin SR, Ardern-Holmes SL, Barker FG 2nd, Blakeley JO, Evans DG, Ferner RE, Hadlock TA, Halpin C; REiNS International Collaboration. Plotkin SR, et al. Among authors: ardern holmes sl. Neurology. 2013 Nov 19;81(21 Suppl 1):S25-32. doi: 10.1212/01.wnl.0000435746.02780.f6. Neurology. 2013. PMID: 24249803 Free PMC article.
Recommendations for imaging tumor response in neurofibromatosis clinical trials.
Dombi E, Ardern-Holmes SL, Babovic-Vuksanovic D, Barker FG, Connor S, Evans DG, Fisher MJ, Goutagny S, Harris GJ, Jaramillo D, Karajannis MA, Korf BR, Mautner V, Plotkin SR, Poussaint TY, Robertson K, Shih CS, Widemann BC; REiNS International Collaboration. Dombi E, et al. Among authors: ardern holmes sl. Neurology. 2013 Nov 19;81(21 Suppl 1):S33-40. doi: 10.1212/01.wnl.0000435744.57038.af. Neurology. 2013. PMID: 24249804 Free PMC article.
Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis.
Ahlawat S, Fayad LM, Khan MS, Bredella MA, Harris GJ, Evans DG, Farschtschi S, Jacobs MA, Chhabra A, Salamon JM, Wenzel R, Mautner VF, Dombi E, Cai W, Plotkin SR, Blakeley JO; Whole Body MRI Committee for the REiNS International Collaboration; REiNS International Collaboration Members 2016. Ahlawat S, et al. Neurology. 2016 Aug 16;87(7 Suppl 1):S31-9. doi: 10.1212/WNL.0000000000002929. Neurology. 2016. PMID: 27527647 Free PMC article.
Neurofibromatosis Type 2.
Ardern-Holmes S, Fisher G, North K. Ardern-Holmes S, et al. J Child Neurol. 2017 Jan;32(1):9-22. doi: 10.1177/0883073816666736. Epub 2016 Sep 29. J Child Neurol. 2017. PMID: 27655473 Review.
Visual field outcomes in children treated for neurofibromatosis type 1-associated optic pathway gliomas: a multicenter retrospective study.
Heidary G, Fisher MJ, Liu GT, Ferner RE, Gutmann DH, Listernick RH, Kapur K, Loguidice M, Ardern-Holmes SL, Avery RA, Hammond C, Hoffman RO, Hummel TR, Kuo A, Reginald A, Ullrich NJ. Heidary G, et al. Among authors: ardern holmes sl. J AAPOS. 2020 Dec;24(6):349.e1-349.e5. doi: 10.1016/j.jaapos.2020.07.013. Epub 2020 Nov 20. J AAPOS. 2020. PMID: 33221469
Systemic therapy in neurofibromatosis type 2.
Lim SH, Ardern-Holmes S, McCowage G, de Souza P. Lim SH, et al. Cancer Treat Rev. 2014 Aug;40(7):857-61. doi: 10.1016/j.ctrv.2014.05.004. Epub 2014 May 16. Cancer Treat Rev. 2014. PMID: 24877986 Review.
29 results